Research ExplorerPublicationsSevere malaria in European 8-year multi-centre observational...

Severe malaria in European 8-year multi-centre observational study

Standard

Severe malaria in European 8-year multi-centre observational study. / Kurth, Florian; Develoux, Michel; Mechain, Matthieu; Malvy, Denis; Clerinx, Jan; Antinori, Spinello; Gjørup, Ida E; Gascon, Joaquím; Mørch, Kristine; Nicastri, Emanuele; Ramharter, Michael; Bartoloni, Alessandro; Visser, Leo; Rolling, Thierry; Zanger, Philipp; Calleri, Guido; Salas-Coronas, Joaquín; Nielsen, Henrik; Just-Nübling, Gudrun; Neumayr, Andreas; Hachfeld, Anna; Schmid, Matthias L; Antonini, Pietro; Lingscheid, Tilman; Kern, Peter; Kapaun, Annette; da Cunha, José Saraiva; Pongratz, Peter; Soriano-Arandes, Antoni; Schunk, Mirjam; Suttorp, Norbert; Hatz, Christoph; Zoller, Thomas.

In: MALARIA J, Vol. 16, No. 1, 31.01.2017, p. 57.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kurth, F, Develoux, M, Mechain, M, Malvy, D, Clerinx, J, Antinori, S, Gjørup, IE, Gascon, J, Mørch, K, Nicastri, E, Ramharter, M, Bartoloni, A, Visser, L, Rolling, T, Zanger, P, Calleri, G, Salas-Coronas, J, Nielsen, H, Just-Nübling, G, Neumayr, A, Hachfeld, A, Schmid, ML, Antonini, P, Lingscheid, T, Kern, P, Kapaun, A, da Cunha, JS, Pongratz, P, Soriano-Arandes, A, Schunk, M, Suttorp, N, Hatz, C & Zoller, T 2017, 'Severe malaria in European 8-year multi-centre observational study', MALARIA J, vol. 16, no. 1, pp. 57. https://doi.org/10.1186/s12936-016-1673-z

APA

Kurth, F., Develoux, M., Mechain, M., Malvy, D., Clerinx, J., Antinori, S., Gjørup, I. E., Gascon, J., Mørch, K., Nicastri, E., Ramharter, M., Bartoloni, A., Visser, L., Rolling, T., Zanger, P., Calleri, G., Salas-Coronas, J., Nielsen, H., Just-Nübling, G., ... Zoller, T. (2017). Severe malaria in European 8-year multi-centre observational study. MALARIA J, 16(1), 57. https://doi.org/10.1186/s12936-016-1673-z

Vancouver

Kurth F, Develoux M, Mechain M, Malvy D, Clerinx J, Antinori S et al. Severe malaria in European 8-year multi-centre observational study. MALARIA J. 2017 Jan 31;16(1):57. https://doi.org/10.1186/s12936-016-1673-z

Bibtex

@article{8afc436fbfc348ecabcacacf348abba6,
title = "Severe malaria in European 8-year multi-centre observational study",
abstract = "BACKGROUND: Malaria remains one of the most serious infections for travellers to tropical countries. Due to the lack of harmonized guidelines a large variety of treatment regimens is used in Europe to treat severe malaria.METHODS: The European Network for Tropical Medicine and Travel Health (TropNet) conducted an 8-year, multicentre, observational study to analyse epidemiology, treatment practices and outcomes of severe malaria in its member sites across Europe. Physicians at participating TropNet centres were asked to report pseudonymized retrospective data from all patients treated at their centre for microscopically confirmed severe Plasmodium falciparum malaria according to the 2006 WHO criteria.RESULTS: From 2006 to 2014 a total of 185 patients with severe malaria treated in 12 European countries were included. Three patients died, resulting in a 28-day survival rate of 98.4%. The majority of infections were acquired in West Africa (109/185, 59%). The proportion of patients treated with intravenous artesunate increased from 27% in 2006 to 60% in 2013. Altogether, 56 different combinations of intravenous and oral drugs were used across 28 study centres. The risk of acute renal failure (36 vs 17% p = 0.04) or cerebral malaria (54 vs 20%, p = 0.001) was significantly higher in patients ≥60 years than in younger patients. Respiratory distress with the need for mechanical ventilation was significantly associated with the risk of death in the study population (13 vs 0%, p = 0.001). Post-artemisinin delayed haemolysis was reported in 19/70 (27%) patients treated with intravenous artesunate.CONCLUSION: The majority of patients with severe malaria in this study were tourists or migrants acquiring the infection in West Africa. Intravenous artesunate is increasingly used for treatment of severe malaria in many European treatment centres and can be given safely to European patients with severe malaria. Patients treated with intravenous artesunate should be followed up to detect and manage late haemolytic events.",
author = "Florian Kurth and Michel Develoux and Matthieu Mechain and Denis Malvy and Jan Clerinx and Spinello Antinori and Gj{\o}rup, {Ida E} and Joaqu{\'i}m Gascon and Kristine M{\o}rch and Emanuele Nicastri and Michael Ramharter and Alessandro Bartoloni and Leo Visser and Thierry Rolling and Philipp Zanger and Guido Calleri and Joaqu{\'i}n Salas-Coronas and Henrik Nielsen and Gudrun Just-N{\"u}bling and Andreas Neumayr and Anna Hachfeld and Schmid, {Matthias L} and Pietro Antonini and Tilman Lingscheid and Peter Kern and Annette Kapaun and {da Cunha}, {Jos{\'e} Saraiva} and Peter Pongratz and Antoni Soriano-Arandes and Mirjam Schunk and Norbert Suttorp and Christoph Hatz and Thomas Zoller",
year = "2017",
month = jan,
day = "31",
doi = "10.1186/s12936-016-1673-z",
language = "English",
volume = "16",
pages = "57",
journal = "MALARIA J",
issn = "1475-2875",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Severe malaria in European 8-year multi-centre observational study

AU - Kurth, Florian

AU - Develoux, Michel

AU - Mechain, Matthieu

AU - Malvy, Denis

AU - Clerinx, Jan

AU - Antinori, Spinello

AU - Gjørup, Ida E

AU - Gascon, Joaquím

AU - Mørch, Kristine

AU - Nicastri, Emanuele

AU - Ramharter, Michael

AU - Bartoloni, Alessandro

AU - Visser, Leo

AU - Rolling, Thierry

AU - Zanger, Philipp

AU - Calleri, Guido

AU - Salas-Coronas, Joaquín

AU - Nielsen, Henrik

AU - Just-Nübling, Gudrun

AU - Neumayr, Andreas

AU - Hachfeld, Anna

AU - Schmid, Matthias L

AU - Antonini, Pietro

AU - Lingscheid, Tilman

AU - Kern, Peter

AU - Kapaun, Annette

AU - da Cunha, José Saraiva

AU - Pongratz, Peter

AU - Soriano-Arandes, Antoni

AU - Schunk, Mirjam

AU - Suttorp, Norbert

AU - Hatz, Christoph

AU - Zoller, Thomas

PY - 2017/1/31

Y1 - 2017/1/31

N2 - BACKGROUND: Malaria remains one of the most serious infections for travellers to tropical countries. Due to the lack of harmonized guidelines a large variety of treatment regimens is used in Europe to treat severe malaria.METHODS: The European Network for Tropical Medicine and Travel Health (TropNet) conducted an 8-year, multicentre, observational study to analyse epidemiology, treatment practices and outcomes of severe malaria in its member sites across Europe. Physicians at participating TropNet centres were asked to report pseudonymized retrospective data from all patients treated at their centre for microscopically confirmed severe Plasmodium falciparum malaria according to the 2006 WHO criteria.RESULTS: From 2006 to 2014 a total of 185 patients with severe malaria treated in 12 European countries were included. Three patients died, resulting in a 28-day survival rate of 98.4%. The majority of infections were acquired in West Africa (109/185, 59%). The proportion of patients treated with intravenous artesunate increased from 27% in 2006 to 60% in 2013. Altogether, 56 different combinations of intravenous and oral drugs were used across 28 study centres. The risk of acute renal failure (36 vs 17% p = 0.04) or cerebral malaria (54 vs 20%, p = 0.001) was significantly higher in patients ≥60 years than in younger patients. Respiratory distress with the need for mechanical ventilation was significantly associated with the risk of death in the study population (13 vs 0%, p = 0.001). Post-artemisinin delayed haemolysis was reported in 19/70 (27%) patients treated with intravenous artesunate.CONCLUSION: The majority of patients with severe malaria in this study were tourists or migrants acquiring the infection in West Africa. Intravenous artesunate is increasingly used for treatment of severe malaria in many European treatment centres and can be given safely to European patients with severe malaria. Patients treated with intravenous artesunate should be followed up to detect and manage late haemolytic events.

AB - BACKGROUND: Malaria remains one of the most serious infections for travellers to tropical countries. Due to the lack of harmonized guidelines a large variety of treatment regimens is used in Europe to treat severe malaria.METHODS: The European Network for Tropical Medicine and Travel Health (TropNet) conducted an 8-year, multicentre, observational study to analyse epidemiology, treatment practices and outcomes of severe malaria in its member sites across Europe. Physicians at participating TropNet centres were asked to report pseudonymized retrospective data from all patients treated at their centre for microscopically confirmed severe Plasmodium falciparum malaria according to the 2006 WHO criteria.RESULTS: From 2006 to 2014 a total of 185 patients with severe malaria treated in 12 European countries were included. Three patients died, resulting in a 28-day survival rate of 98.4%. The majority of infections were acquired in West Africa (109/185, 59%). The proportion of patients treated with intravenous artesunate increased from 27% in 2006 to 60% in 2013. Altogether, 56 different combinations of intravenous and oral drugs were used across 28 study centres. The risk of acute renal failure (36 vs 17% p = 0.04) or cerebral malaria (54 vs 20%, p = 0.001) was significantly higher in patients ≥60 years than in younger patients. Respiratory distress with the need for mechanical ventilation was significantly associated with the risk of death in the study population (13 vs 0%, p = 0.001). Post-artemisinin delayed haemolysis was reported in 19/70 (27%) patients treated with intravenous artesunate.CONCLUSION: The majority of patients with severe malaria in this study were tourists or migrants acquiring the infection in West Africa. Intravenous artesunate is increasingly used for treatment of severe malaria in many European treatment centres and can be given safely to European patients with severe malaria. Patients treated with intravenous artesunate should be followed up to detect and manage late haemolytic events.

U2 - 10.1186/s12936-016-1673-z

DO - 10.1186/s12936-016-1673-z

M3 - SCORING: Journal article

C2 - 28143519

VL - 16

SP - 57

JO - MALARIA J

JF - MALARIA J

SN - 1475-2875

IS - 1

ER -